



## Press Release

### For further information please contact:

David Brown, Ph.D  
President & Chief Executive Officer  
Cellzome AG  
Meyerhofstr. 1  
69117 Heidelberg, Germany  
Tel: +49-6221-137 57-100  
Fax: +49-6221-137 57-201  
press@cellzome.com

### FOR IMMEDIATE RELEASE

## Cellzome Signs Research Collaboration with Bayer HealthCare AG

### Heidelberg, Germany, December 8, 2003 –

Cellzome announced today that it has signed a research agreement with Bayer HealthCare. Under the terms of the agreement, which provides for technology access and research funding, the companies will collaborate in leveraging Cellzome's drug proteomics platform to profile Bayer HealthCare lead compounds. Cellzome's chemical proteomics approach will be utilized to identify the protein interaction profiles of several lead compounds from a variety of therapeutic areas, facilitating further drug development at Bayer HealthCare.

"We are delighted to have secured this collaboration with Bayer HealthCare and believe this is the first step towards a long-term strategic relationship between the companies", commented Dr. David Brown Chief Executive at Cellzome.

Cellzome's drug proteomics platform utilizes both chemical proteomics and pathway expansion. With its chemical proteomics capabilities, Cellzome takes existing drugs and pharmacologically active compounds to identify their protein targets in the human proteome. These protein targets are then mapped on cellular pathways using Cellzome's pathway expansion technology, detecting the link between the drug, its protein target and the disease pathway. The technology platform allows efficient and scalable chemical proteomics and pathway expansion experiments to be performed in a broad variety of cell types and tissues.

A world class mass spectrometry capability guarantees quality controlled, highly sensitive protein identification. A strong, customized IT infrastructure enables efficient sample and data management coupled to excellent bioinformatics annotation allows in-depth interpretation in the context of the rapidly growing Cellzome data set. This process generates a strong pipeline of opportunities both for Cellzome's in-house drug discovery as well as for partnerships.

### About Cellzome AG

Cellzome is a drug discovery company building an R&D pipeline in chronic diseases, with a primary focus on Alzheimer's Disease. Cellzome is leveraging its powerful drug proteomics engine to generate an ongoing pipeline, both for in-house drug development and through partnership. Cellzome's unique combination of chemical proteomics and pathway expansion enables more efficient drug discovery by focusing on the interface between validated disease pathways, tractable medicinal chemistry and druggable targets.

Founded at the European Molecular Biology Laboratory (EMBL) in May 2000, Cellzome has combined scientific leadership with experienced pharmaceutical management. The company currently has approx. 100 employees with offices in Heidelberg, Germany and London, UK. To learn more about Cellzome visit [www.cellzome.com](http://www.cellzome.com)